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Background and Aims: Ustekinumab is approved for the treatment of Crohn’s disease [CD]. 
Systematically registered prospective real-world data are scarce. We therefore aimed to study the 
effectiveness, safety and usage of ustekinumab for CD in everyday practice.
Methods: We prospectively enrolled CD patients initiating ustekinumab in regular care between 
December 2016 and January 2019. Clinical (Harvey Bradshaw Index [HBI]), biochemical (C-reactive 
protein [CRP] and faecal calprotectin [FCP]), extra-intestinal manifestations and, peri-anal fistula 
activity, ustekinumab dosage, concomitant medication use, and adverse events were documented 
at weeks 0, 12, 24, and 52. The primary outcome was corticosteroid-free clinical remission.
Results: In total, 221 CD patients were included (98.6% anti-tumour necrosis factor [TNF] and 
46.6% vedolizumab exposed) with a median follow-up of 52.0  weeks [interquartile range 49.3–
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respectively. An initial dosing schedule of 8  weeks, compared to 12  weeks, correlated with a 
lower discontinuation rate [20.0% vs 42.6%, p = 0.01], but comparable corticosteroid-free clinical 
remission at week 52 (46.3% [q8w] vs 34.6% [q12w], p = 0.20). There was no clinical benefit of 
combination therapy after 52 weeks when compared to ustekinumab monotherapy [combi 40.6% 
vs mono 36.0%, p = 0.64]. At baseline, 28 patients had active peri-anal fistula, of whom 35.7% 
showed complete clinical resolution after 24 weeks. During follow-up we encountered six severe 
infections [3.5 per 100 patient-years], with all patients being on concomitant immunosuppressant 
therapies. Ustekinumab treatment discontinuation was observed in 75 [33.9%] patients mainly due 
to lack of response.
Conclusion: Ustekinumab is a relatively safe and effective treatment option for CD patients with 
prior failure of anti-TNF and anti-integrin therapies.
Key Words: Ustekinumab; Crohn’s disease; ICC Registry
1. Introduction
Ustekinumab is a fully human monoclonal antibody targeting the p40 
subunit of interleukin-12 and interleukin-23. It has been approved 
for the treatment of Crohn’s disease [CD] in the Netherlands since 
November 2016.1 The results of the registration trial [IM-UNITI] 
showed a 46.9% [vs 29.8% placebo] corticosteroid-free clinical 
remission rate after 44 weeks of treatment with no significant dif-
ference between the 8- and 12-weekly dosing interval. However, a 
large proportion of patients receiving ustekinumab in the induction 
studies [64.3% and 47.3% in UNITI 1 and UNITI 2, respectively] 
were not enrolled in the IM-UNITI maintenance trial due to lack of 
clinical response to induction therapy. Furthermore, to participate 
in the UNITI trials, patients had to fulfil over 20 inclusion and sat-
isfy more than 30 exclusion criteria, illustrating a strict trial design 
that does not accurately reflect routine care.1,2 Therefore, robust real-
world effectiveness and safety data are needed.
Real-world observational studies allow for assessment of effect-
iveness and safety of a treatment used in the general population. To 
date, the real-world experience of ustekinumab in terms of effect-
iveness and safety has been assessed in several studies.3–11 However, 
these studies were limited by short-term follow-up, small sample 
sizes, retrospective study designs, limited objective outcome param-
eters, and a variation in induction protocols not comparable with 
current standard care (e.g. subcutaneous [SC] injections, different 
doses within and between studies). Hence, systematic, uniform and 
prospective collected data are warranted in order to interpret the 
effectiveness and safety outcomes of new therapies. For this pur-
pose, we developed the Dutch Initiative on Crohn and Colitis [ICC] 
Registry: a nationwide registry for inflammatory bowel disease 
[IBD] patients starting novel therapies in standard care with a sys-
tematic follow-up protocol.
The aim of the current study was to describe the effectiveness, 
safety and use of ustekinumab treatment in CD patients in a real-life 
setting using the ICC Registry. Secondly, we aimed to assess pre-
dictors of clinical response.
2. Methods
2.1. Study design and setting
The ICC Registry is a nationwide, observational registry with sys-
tematic, prospective follow-up of IBD patients starting designated 
IBD therapies in the Netherlands.12,13 Currently, eight academic 
centres and three non-academic centres participate in this registry, 
which started in 2014. The general aim of the ICC Registry is to 
evaluate the therapeutic effectiveness and safety of specific IBD ther-
apies in a real-world setting. Enrolled patients follow a pre-defined 
schedule of out-patient visits designed to closely follow regular care. 
Visits are scheduled at initiation of therapy [baseline], weeks 12, 24, 
52 and 104 or until medication is discontinued. Data collection is 
done using an electronic case report form [eCRF] with automated 
reminders to improve adherence to the protocol. The eCRF is filled 
out by the treating physician or IBD nurse at every visit. The ICC 
Registry platform is used to systematically document the effective-
ness and safety of ustekinumab therapy in CD patients.
2.2. Participants
Following formal approval of ustekinumab by regulatory author-
ities, CD patients initiating this therapy in the Netherlands between 
November 2016 and January 2019 were enrolled at the participating 
centres. Patients ≥16 years old were eligible for inclusion with a con-
firmed clinical, endoscopic and/or histological diagnosis of CD. The 
decision to start ustekinumab therapy was at the discretion of the 
treating physician. There were no exclusion criteria. The initial intra-
venous [IV] infusion with ustekinumab at baseline was weight-based 
following label [260 mg < 55 kg, 390 mg between 55 and 85 kg, 
520 mg > 85 kg]. The first subcutaneous [SC] induction dose was 
administered at week 8 with a 90 mg injection followed by a subse-
quent maintenance SC dosing of 90 mg every 8 or 12 weeks, at the 
discretion of the treating physician. All patients with a follow-up of 
at least 12 weeks measured from their initial ustekinumab infusion 
were included in the current study. Patients with clinical disease ac-
tivity at baseline (e.g. Harvey Bradshaw Index [HBI] > 4) were used 
to determine the effectiveness outcomes while all enrolled patients 
were used to determine safety outcomes.
2.3. ICC Registry variables
Documented baseline characteristics included sex, age, weight, 
height, disease duration, disease behaviour and location according to 
the Montreal classification at diagnosis and maximum extent at in-
clusion, previous medication, disease severity [HBI ≤ 4 = remission, 
5–7 = mild activity, 8–16 = moderate activity, >16 = severe activity], 
history of bowel-related surgery and co-morbidities. During the 
scheduled visits we systematically assessed clinical disease activity 
using the HBI and physician global assessment [PGA]. Furthermore, 
information about dosage and concomitant medication use was re-
gistered. Disease-related adverse events such as hospitalization, sur-
gery and peri-anal surgery were documented. Medication-related 
adverse events were classified as probably, possibly and not related. 
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Infections were classified as mild: no use of antibiotics or antiviral 
mediation necessary; moderate: oral antibiotic or antiviral medica-
tion; or severe: hospitalization or IV administrated antibiotics/anti-
viral medication. Routine laboratory tests were requested at each 
visit, including C-reactive protein [CRP] and faecal calprotectin 
[FCP].
2.4. Outcomes and definitions
The primary objective of this study was to determine the propor-
tion of patients in corticosteroid-free clinical remission at week 52. 
Secondary effectiveness outcomes included: clinical response, clin-
ical remission, biochemical remission, combined corticosteroid-free 
clinical and biochemical remission [combined end point], fistula 
response and remission, extra-intestinal manifestation [EIM] re-
mission, ustekinumab treatment escalation, intestinal and peri-anal 
surgery, and discontinuation of ustekinumab. Corticosteroid-free 
clinical remission was compared between 12-weekly [q12w] and 
8-weekly [or less] [q8w] treatment intervals, between anti-integrin 
naive and exposed patients, and between patients with and without 
concomitant immunosuppressive therapy [thiopurines or metho-
trexate] at baseline. Additionally, predictors of corticosteroid-free 
clinical remission at week 52 were determined. Clinical remission 
was defined as HBI ≤ 4 points. Clinical response was defined as a re-
duction of at least 3 points in HBI compared to baseline. Biochemical 
remission was defined as a CRP concentration ≤5 mg/L and a FCP 
level of ≤200 µg/g [when available]. Fistula remission was defined 
as complete clinical resolution of all peri-anal fistulas at physical 
examination. Fistula response was defined as a decrease of 50% 
in the number of actively draining peri-anal fistulas or a decrease 
in drainage [graded as: spontaneous drainage, drainage after soft 
manual pressure, and no drainage after manual pressure].14 EIMs 
that were documented included: arthralgia, uveitis, aphthous stoma-
titis, erythema nodosum and pyoderma gangrenosum. EIM remis-
sion was assessed by the treating physician. Reasons for treatment 
discontinuation were at the discretion of the treating physician. The 
safety outcomes included the number of drug-related adverse events, 
mild, moderate or severe infections [see definitions in previous para-
graph], and disease-related hospitalizations per 100 patient-years.
Follow-up time was determined based on the date of the initial 
IV infusion with ustekinumab until the last visit used in the analysis. 
Patients who discontinued ustekinumab treatment due to a primary 
or secondary non-response, adverse events, or at patient request 
without long-term sustained remission were considered a treatment 
failure and classified as non-responders. Patients who discontinued 
ustekinumab treatment because of pregnancy or long-term sustained 
remission were considered censored cases. Patients with inadequate 
follow-up time for a specific visit, either responders or non-
responders, were considered censored cases and were not included 
in the analysis of that visit. For example, a patient with 32 weeks of 
follow-up would have contributed to the 24-week analysis but not 
the 52-week analysis.
2.5. Statistical methods
Patients were analysed on an intention-to-treat basis. Continuous 
variables were presented as means with standard deviation [SD] 
or as median with interquartile range [IQR] depending on the nor-
mality of the underlying distribution. Variables were subsequently 
compared using a paired or independent T-test or Mann–Whitney U 
test. Categorical variables were presented as percentages and com-
pared by using the chi-square or Fisher’s exact test. The Kaplan–
Meier method was used to assess drug survival. Variables associated 
with week 52 corticosteroid-free clinical remission were explored 
using binary logistic regression. Multivariate analysis was performed 
on variables with p  <  0.2 on univariate analysis using backward 
step-wise logistic regression. A two-sided p value of 0.05 or less was 
considered statistically significant. All data analyses were performed 
using IBM SPSS Statistics for Windows, version 24.0. [IBM].
2.6. Ethical consideration
The study was reviewed and approved by the Committee on 




Patient baseline characteristics are detailed in Table 1. Among the 
232 CD patients enrolled in the ICC Registry, 221 were followed for 
at least 12 weeks and were included in the analysis. Enrolled patients 
were followed for a median of 52.0 weeks [IQR 49.3–58.4]. Patients 
were predominantly female [60.2%] with a median disease duration 
Table 1. Baseline patient characteristics 
Baseline characteristics  N = 221
Agea Median [IQR] 38.2 [29.3–52.2]
Sex, male N [%] 88 [39.8]
Body mass indexa Mean [SD] 23.7 [5.0]
Disease duration, years Median [IQR] 12.3 [7.5–19.3]
Follow-up duration, years Median [IQR] 52.0 [49.3–58.4]
Disease locationb   
 Ileum N [%] 68 [30.8]
 Colon N [%] 76 [34.4]
 Ileocolonic N [%] 77 [34.8]
Upper GI tract involvementb N [%] 12 [5.4]
Disease behaviourb   
 Inflammatory disease N [%] 113 [51.1]
 Stricturing disease N [%] 63 [28.5]
 Penetrating disease N [%] 40 [18.1]
 Unknown N [%] 5 [2.3]
Peri-anal diseaseb N [%] 37 [16.7]
Prior intestinal resections N [%] 137 [62.0]
Prior peri-anal interventions N [%] 47 [21.3]
Prior anti-TNF therapy   
 ≥1 N [%] 218 [98.6]
 ≥2 N [%] 162 [73.3]
 3 N [%] 11 [5.0]
Prior vedolizumab N [%] 103 [46.6]
Prior anti-TNF and vedolizumab N [%] 102 [46.2]
Disease activitya   
 Harvey Bradshaw Index Median [IQR] 7 [4–11]
 CRP, mg/L Median [IQR] 9 [3–20]
 Faecal calprotectin, µg/g Median [IQR] 699 [211–1536]
Concomitant medicationa   
 Corticosteroids N [%] 35 [15.8]
 Corticosteroids range mg [IQR] 20 [19–30]
 Immunosuppressants N [%] 44 [19.9]
  Both corticosteroids and 
immunosuppressants
N [%] 12 [5.4]
 Corticosteroids range mg [IQR] 25 [13–38]
IQR, interquartile range; SD, standard deviation; GI, gastrointestinal; anti-
TNF: anti-tumour necrosis factor; CRP, C-reactive protein.
aAt inclusion.
bMaximum extent until inclusion.
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of 12.3 years [IQR 7.5–19.2]. One-third of patients had ileocolonic 
disease [n = 77/221, 34.8%], and a penetrating disease phenotype 
was documented in 18.1% [n = 40/221] of the patients at maximum 
extent of their disease course. In total, 216 patients [97.7%] were 
previously exposed to thiopurines or methotrexate and 218 patients 
[98.6%] had failed at least one anti-tumour necrosis factor [anti-
TNF] agent. In addition, 162 patients [73.3%] previously failed 
two or more anti-TNF agents and 103 [46.6%, only one patient 
was anti-TNF naïve] patients used vedolizumab before initiating 
ustekinumab treatment. A history of intestinal resections was docu-
mented in 137 patients [62.0%] and 47 [21.3%] had a history of 
peri-anal surgical interventions.
At baseline, clinical disease activity was seen in 153 CD pa-
tients [69.2%] with a median HBI of 10 [IQR 7–13], median CRP 
concentration of 9.0 mg/L [IQR 3.0–20.0] and median FCP level 
of 686 µg/g [IQR 205–1595] [Supplementary Table 1]. The ma-
jority [59.5%] of patients started ustekinumab as monotherapy, 
i.e. without concomitant immunosuppressive medication. Of the 
68 patients without clinical disease activity [HBI  <  5] at base-
line, 86.8% [n  =  59/68] showed disease activity based on ac-
tive fistula, inflammatory biomarkers, endoscopy or radiology 
[Supplementary Table 2]. These patients were not included in the 
effectiveness analysis.
3.2. Corticosteroid-free clinical remission
Of the patients with clinical disease activity at baseline [HBI > 4], 
the proportion of patients in corticosteroid-free clinical remission at 
weeks 12, 24 and 52 was 24.2% [n = 37/153], 38.2% [n = 58/152] 
and 37.1% [n = 49/132], respectively [Figure 1]. Of the 57 patients in 
corticosteroid-free clinical remission at week 24, 58.8% [n = 30/51] 
remained so until week 52 [Figure 1].
As sensitivity analysis we performed three additional analyses in 
patients with [a] endoscopic disease activity at baseline, [b] biochem-
ical disease activity at baseline and [c] all patients [including those in 
clinical remission at baseline].
Endoscopic evaluation was performed in 107 patients at base-
line, and all had endoscopic disease activity. Of these patients the 
corticosteroid-free clinical remission rate at weeks 12, 24 and 52 was 
28.0% [n = 30/107], 39.3% [n = 42/107] and 37.8% [n = 37/98], 
respectively.
Biochemical disease activity was observed in 154 patients at 
baseline. Of these patients the corticosteroid-free clinical remis-
sion rate at weeks 12, 24 and 52 was 35.1% [n = 54/154], 45.8% 
[n = 70/153] and 44.6% [n = 58/130], respectively.
At baseline, 68 [30.8%] were in clinical remission [i.e. HBI ≤ 4]. 
When analysing all patients receiving ustekinumab regardless of clin-
ical disease activity at baseline [n = 221], the proportion of patients 
in corticosteroid-free clinical remission at weeks 0, 12, 24 and 52 
was 25.8% [n = 57/221], 35.7% [n = 79/221], 46.6% [n = 102/219] 
and 41.8% [n = 79/189], respectively.
Next, corticosteroid-free clinical remission rates were compared 
at different time points according to ustekinumab maintenance 
interval [q8w vs q12w], prior anti-integrin exposure and concomi-
tant immunosuppressive therapy at baseline. Only patients with clin-
ical disease activity at baseline were analysed.
3.2.1. Q12w vs q8w
Eighty-five patients started ustekinumab maintenance therapy on 
an q8w interval and 54 patients received ustekinumab on a q12w 
maintenance interval. Fourteen patients discontinued ustekinumab 
treatment before week 12 [11 primary non-response, two adverse 
events, one at request of patient] and were not included in the 
comparative analysis. Baseline characteristics were comparable 
between the subgroups. However, the HBI was significantly higher 
at week 12 for the q8w interval (q8w 6 [4–9] vs q12w 5 [3–8], 
p = 0.04) [Supplementary Table 3]. The proportion of patients in 
corticosteroid-free clinical remission at weeks 12, 24 and 52 was 
21.2% [q8w] vs 35.2% [q12w] p = 0.07, 46.4% [q8w] vs 35.2% 





































Week 12 Week 24 Week 52
Figure 1. Proportion of patients with clinical response, clinical remission and corticosteroid-free clinical remission.















































































































































































Week 12 Week 24 Week 52
Figure 2. Proportion of patients in corticosteroid-free clinical remission: [A] 12 weekly vs 8 weekly maintenance interval; [B] anti-TNF exposure alone vs anti-
TNF and anti-integrin exposed at baseline; [C] concomitant immunosuppressants [thiopurines or methotrexate] at baseline vs ustekinumab monotherapy at 
baseline.
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Twenty-two per cent [n = 19/85, one due to pregnancy] of the 
patients on a q8w interval discontinued ustekinumab treatment after 
a median treatment duration of 30.6 weeks [IQR 19.7–40.4] while 
42.6% [n = 23/54] of the patients on a q12w interval discontinued 
treatment after a median treatment duration of 30.1  weeks [IQR 
20.4–43.3] [p = 0.02] [Figure 4B]. Lack of response was the main 
reason for treatment discontinuation in both groups [Supplementary 
Table 4]. Adverse events between the groups were comparable 
[Supplementary Table 5].
3.2.2. Anti-TNF exposure alone vs anti-TNF and anti-integrin 
exposure
Before starting ustekinumab, 75 patients [50%] were exposed to both 
anti-TNF and vedolizumab while 75 patients were only exposed to anti-
TNF. Baseline characteristics were comparable between the subgroups, 
except for the number of anti-TNF therapies in the medical history [≥2 
anti-TNFs: anti-TNF exposed 68.0% vs anti-TNF/integrin exposed 
82.6%, p = 0.04] and FCP level at baseline (anti-TNF exposed 506 µg/g 
[IQR 93–1303] vs 746  µg/g [IQR 417–1800] anti-TNF/integrin ex-
posed, p = 0.04) [Supplementary Table 6]. At week 52, there was a non-
significant difference in the proportion of patients in corticosteroid-free 
clinical remission (anti-TNF exposed 42.9% [n = 27/63] vs anti-TNF/
integrin exposed 31.3% [n = 21/67], p = 0.17) [Figure 2B]. There was 
also a non-significant difference in discontinuation rate between the 
groups (anti-TNF exposed 30.7% [n = 23/75] vs anti-TNF/integrin ex-
posed 42.7% [n = 32/75], p = 0.13). Lack of response was the main 
reason for discontinuation of ustekinumab treatment [anti-TNF ex-
posed 65.2%, anti-TNF/integrin exposed 78.1%].
3.2.3. With or without concomitant immunosuppressants
At baseline, 33 patients [21.6%] initiated ustekinumab while on con-
comitant immunosuppressants [thiopurines or methotrexate], and 120 
[78.4%] started ustekinumab as monotherapy. Baseline characteris-
tics were significantly different regarding prior anti-integrin exposure 
(combi 33.3% [n  =  11/33] vs mono 54.2% [n  =  65/120] p  =  0.03) 
and HBI (combi 8 [IQR 6–11] vs mono 10 [IQR 7–13] p  =  0.048) 
[Supplementary Table 7]. At week 52, there was no significant difference 
between corticosteroid-free clinical remission (combi 40.6% [n = 13/32] 
vs mono 36.0% [n = 36/100] p = 0.64) [Figure 2C]. There was no signifi-
cant difference in discontinuation rate between the two groups (combi 
42.4% [n = 14/33] vs mono 35.0% [n = 42/120] p = 0.43).
3.3. Clinical response and remission
The proportion of patients with a clinical response to ustekinumab 
therapy at weeks 12, 24 and 52 was 47.7% [n = 73/153], 46.1% 
[n  =  70/152] and 42.4% [n  =  56/132], respectively [Figure 1]. 
The proportion of patients in clinical remission at weeks 12, 24 
and 52 was 30.7% [n = 47/153], 40.1% [n = 61/152] and 39.4% 
[n = 52/132], respectively [Figure 1].
3.4. Biochemical disease activity
The proportion of patients in biochemical remission at weeks 12, 24 
and 52 was 23.9% [n = 32/135], 24.6% [n = 30/122] and 26.4% 
[n = 32/121], respectively. When missing data were imputed as non-
responders, the proportion of patients in biochemical remission at 
weeks 12, 24 and 52 was 20.9% [n = 32/153], 19.7% [n = 30/152] 
and 24.2% [n = 32/132] , respectively. The median CRP concentra-
tion of patients treated with ustekinumab at weeks 0, 12, 24 and 52 
was 9 mg/L [IQR 3–20], 5 mg/L [IQR 2–12], 6 mg/L [IQR 2–12] and 
4 mg/L [IQR 2–9], respectively [Figure 3A]. The median FCP level 
at weeks 0, 12, 24 and 52 was 686 µg/g [IQR 205–1596], 405 µg/g 
[IQR 144–1017], 222  µg/g [IQR 85–697] and 176  µg/g [IQR 
65–688], respectively [Figure 3B]. FCP was available for 71.0% of 
patients to determine biochemical remission.
3.5. Combined end point
Of the 153 patients with clinical disease activity at baseline, the pro-
portion of patients in combined corticosteroid-free clinical and bio-
chemical remission at weeks 12, 24 and 52 was 5.2% [n = 7/135], 
13.9% [n = 17/122] and 18.2% [n = 22/121], respectively.
3.6. Clinical factors associated with corticosteroid-
free clinical remission
Univariate and multivariate predictors of week 52 corticosteroid-
free clinical remission are detailed in Table 2. In the multivariate ana-
lysis only body mass index [BMI] per point (odds ratio [OR] 0.91; 
95% confidence interval [CI] 0.83–1.00) was associated with lower 
rates of corticosteroid-free clinical remission at week 52. Disease lo-
cation and behaviour were not associated with corticosteroid-free 
clinical remission. Upper-gastrointestinal tract involvement showed 
a numerical trend towards increased response, but not reaching 
statistical significance as a univariable predictor [OR 3.72; 95% CI 
0.89–15.6]. However, this difference was less pronounced when as-
sessed as a multivariable predictor [OR 3.87; 95% CI 0.63–23.60]. 
Only three patients were anti-TNF naïve, and hence this param-
eter could not be assessed for prediction of response to therapy. 
Comorbidities did not have a significant effect on corticosteroid-free 
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Figure 3. [A] Median C-reactive protein concentration with interquartile 
range. [B] Median faecal calprotectin concentration with interquartile rage.
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3.7. Peri-anal manifestations
At baseline, 28 patients [12.7%] had one or more active peri-anal 
fistulas. Seventeen [60.7%] patients had spontaneous drainage 
and 11 [39.2%] patients had drainage after gentle manual pres-
sure. After 12 weeks of treatment, four patients [14.3%] had com-
plete clinical remission of all peri-anal fistulas while four [14.3%] 
patients showed a response based on decrease in fistula drainage. 
After 24 weeks of treatment, ten patients [35.7 %] had complete 
resolution of all fistulas while four patients [14.3%] showed 
clinical response. Four patients underwent peri-anal procedures 
during follow-up. One patient underwent seton placement and 
was followed for 24 weeks without a decrease in fistula drainage. 
One patient developed an active draining fistula after 24  weeks 
of ustekinumab treatment with active luminal disease and was 
consequently treated with a seton placement; drainage did not de-
crease during follow-up. The third patient with an active draining 
fistula at baseline was treated for 8 months without fistula response 
to ustekinumab treatment. The last patient underwent a seton 
placement when treatment was discontinued. Two additional pa-
tients reported anal fissures at baseline, one of whom responded 
to ustekinumab treatment. All four patients with new peri-anal ab-
scesses at baseline achieved remission during follow-up.
3.8. Extra-intestinal manifestations
At baseline, 56 [25.3%] patients experienced EIMs: 44 patients re-
ported arthralgia, three uveitis, seven aphthous stomatitis and two 
erythema nodosum. During the entire follow-up period remission 
was achieved in 24 [54.5%] patients with arthralgia, all patients 
Table 2. Univariable and multivariable predictors for corticosteroid-free remission at 52 weeks
 
Univariable analyses Multivariable analyses
OR 95% CI p value OR 95% CI p value
Age at inclusion 1.01 0.98–1.03 0.95    
Weight, kg 0.98 0.96–1.00 0.11    
BMI per point 0.92 0.84–1.00 0.05 0.91 0.83–1.00 0.05
Sex       
 Male Ref      
 Female 0.84 0.44–1.93 0.84    
Disease duration 0.98 0.95–1.01 0.23    
Disease locationa   0.55    
 Ileum Ref      
 Colon 1.66 0.64–4.30 0.30    
 Ileocolonic 1.53 0.61–3.83 0.37    
Upper GI tract involvementa       
 No Ref      
 Yes 3.72 0.89–15.6 0.07 3.87 0.63–23.6 0.14
Disease behavioura   0.58    
 Inflammatory disease Ref      
 Stricturing disease 0.96 0.40–2.31 0.92    
 Penetrating disease 1.79 0.74–4.33 0.20    
Peri-anal disease       
 No Ref      
 Yes 1.01 0.98–1.04 0.69    
Active fistula       
 No Ref      
 Yes 2.11 0.79–5.62 0.14 1.77 0.50–6.24 0.37
Prior intestinal resections       
 No Ref      
 Yes 0.82 0.40–1.69 0.59    
Anti-integrin exposure       
 No Ref      
 Yes 0.57 0.28–1.17 0.13 0.45 0.18–1.16 0.10
Clinical disease activityb   0.19   0.19
 Mild [HBI 5–7] Ref      
 Moderate [HBI 8–16] 0.49 0.21–1.11 0.09 0.37 0.12–1.08 0.07
 Severe [HBI > 16] 0.42 0.11–1.61 0.21 0.46 0.06–3.55 0.46
Biochemical disease activityb       
 CRP, mg/L 1.00 0.99–1.02 0.88    
 Leucocytes, ×109/L 0.94 0.84–1.05 0.28    
 Faecal calprotectin, µg/g 1.00 1.00–1.00 0.27    
Concomitant medicationb       
 Corticosteroids 0.71 0.30–1.66 0.43    
 Immunosuppressant 1.22 0.54–2.75 0.64    
OR, odds ratio; CI, confidence interval; BMI, body mass index; GI gastrointestinal; HBI, Harvey Bradshaw Index; CRP, C-reactive protein.
aMaximum extent until inclusion.
bAt baseline.
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with uveitis [100%], all patients with aphthous stomatitis [100%] 
and one with erythema nodosum [50%]. During follow-up a total 
of 48 [21.7%] patients developed new EIMs: 37 patients developed 
arthralgia, four uveitis, four aphthous stomatitis and three erythema 
nodosum. Of the newly developed EIMs, 12 [32.4%] patients with 
arthralgia, one [25%] with aphthous stomatitis and two [66.7%] 
with erythema nodosum achieved remission during follow-up.
3.9. Safety profile
The entire cohort of 221 patients were included in our safety ana-
lysis [including patients with HBI < 5 at baseline] and were followed 
for approximately 196 patient-years. Eight patients discontinued 
ustekinumab treatment due to adverse events [4.1 per 100 patient-
years] after a median treatment duration of 18.1 weeks [IQR 0.57–
34.5]. Detailed information is shown in Table 3. The serious adverse 
events requiring treatment discontinuation were: four cases of severe 
arthralgia, one infusion reaction, one vasculitis, one severe head-
ache and one patient with recurrent infections. During follow-up 
we encountered nine probably related [4.6 per 100 patient-years] 
and 31 possibly related [15.8 per 100 patient-years] adverse events. 
Headaches, cutaneous rash and arthralgia were the most com-
monly described adverse events. Additionally, we documented six 
severe infections [3.1 per 100 patient-years] in patients all treated 
with concomitant corticosteroids, immunosuppressants or both 
[Supplementary Table 7], 25 moderate infections [12.7 per 100 
patient-years] and 39 mild infections [19.9 per 100 patient-years] 
[Table 3]. One 59-year-old female patient with an extensive med-
ical history was treated for 12 months with ustekinumab when she 
was diagnosed with a malignancy [peritoneal carcinoma]. She died 
shortly after due to an abdominal sepsis after a colonoscopic perfor-
ation. One patient discontinued ustekinumab due to pregnancy. At 
week 25 of her pregnancy she received her last SC injection. After an 
uncomplicated pregnancy she gave birth to a healthy child.
In total, 46 patients required hospitalization [23.5 per 100 
patient-years] during ustekinumab treatment. Six patients were hos-
pitalized while starting ustekinumab treatment. The effectiveness 
outcomes of the patients who were hospitalized at baseline were 
not significantly different from the non-hospitalized cohort. During 
follow-up 14 patients required surgery, nine patients continued 
ustekinumab treatment of whom five maintained steroid-free clin-
ical remission until the end of follow-up, and three patients with 
endoscopic evaluation after 6  months showed endoscopic remis-
sion. Four patients underwent surgery and continued ustekinumab 
treatment but follow-up was too short to assess the effectiveness 
outcomes. Five other patients discontinued ustekinumab treatment 
perioperatively [lack of response: 3, adverse events: 2].
3.10. Maintenance interval between ustekinumab 
injections
After the initial IV treatment the first SC dose of 90 mg was ad-
ministered to 216 patients [97.7%] at week 8, while three patients 
[1.4%] received their first SC dose at week 4, one patient [0.5%] 
at week 12, and one patient [0.5%] did not receive a single SC in-
jection. At week 12 [Figure 4A, B], 65.0% [n = 132/203] continued 
their maintenance interval at one SC injection every 8 weeks or less 
[q4w: 2, q6w: 2, q7w: 1]. At week 24, 77.3% [n = 133/172] were 
injected every 8 weeks or less [q4w: 3, q6w: 2, q7w: 1]. At week 
52, 85.2% [n  =  98/115] received the injection every 8  weeks or 
less [q4w: 11, q6w: 5, q7w: 1]. At week 52, 11 patients were on a 
q4w interval and 72.7% were in corticosteroid-free clinical remis-
sion at that time point. In total, 31 patients underwent dose escal-
ation from q12w to q8w interval. Of these patients, 17 achieved or 
maintained steroid-free clinical remission during follow-up. During 
follow-up seven patients received IV re-induction with a 42.9% 
recapture response rate. Four patients with extensive surgical and 
medical history and limited remaining treatment options received 
an IV re-induction with a subsequent q4w interval but failed to 
achieve remission. Three patients with a loss of response [one after 
24 weeks, two after 1 year] received successful IV re-induction and 
maintained remission during follow-up.
3.11. Ustekinumab drug survival
Cumulative ustekinumab drug survival is detailed in Figure 4. Of 
221 patients, 75 [33.9%] discontinued ustekinumab after a me-
dian treatment duration of 24.6 weeks [IQR 15.9–37.8]. The main 
reasons for discontinuing treatment were lack of response [70.7%, 
Table 3. Adverse events
Adverse events Total follow-up years: 196.1
Possibly related 31 [15.8 per 100 patient-years]




 Vascular event 2
 Hair loss 2
 Fatigue 1
 Panic attacks 1
 Dry mouth 1
  Severe hypocalcaemia and 
hypomagnesaemia
1
 Nervous system event 1
 Eye condition 1
Probably related 9 [4.6 per 100 patient-years]
 Cutaneous rash 3
 Arthralgia 2
 Headache 1
 Injection reactions 1
 Eye condition 1
 Hair loss 1
Serious adverse events 8 [4.1 per 100 patient-years]
 Arthralgia 4 
 Infusion reaction 1 
 Vasculitis 1 
 Recurrent infections 1 
 Severe headache 1
Mild infections 39 [19.9 per 100 patient-years]
 Upper respiratory tract 16
 Flu-like symptoms 10
 Gastrointestinal 6
 Soft tissue 3
 Cold sore 3
 Urinary tract 1
Moderate infections 25 [12.7 per 100 patient-years]
 Urinary tract 7
 Upper respiratory tract 7
 Skin 3
 Soft tissue 3
 Lower respiratory tract 3
 Gynaecological 1
 Flu-like 1
Severe infections 6 [3.1 per 100 patient-years]
 Gastrointestinal 4
 Central catheter 1
 Herpes zoster 1
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n = 53], adverse events [10.7%, n = 8] and loss of response [8.0%, 
n = 6] [Table 4]. The probability of remaining on ustekinumab treat-
ment after 52 weeks was 62.9% [Figure 5A]. There were no discon-
tinuations because of stable remission.
4. Discussion
We assessed real-world effectiveness, safety and dosing of ustekinumab 
treatment for CD patients in the ICC registry, a prospective multicentre 
registry in the Netherlands. This cohort of biological-experienced 
patients [99% anti-TNF, 47% vedolizumab] showed corticosteroid-
free clinical remission rates after 24 and 52 weeks of ustekinumab 
treatment of 38% and 37%, respectively. A q8w maintenance interval 
at week 12 correlated with a lower discontinuation rate during 
follow-up compared to a q12w interval. Eighty-five per cent of the pa-
tients received a q8w interval at week 52. After 24 weeks of treatment, 
36% achieved clinical remission of peri-anal fistulas. Ustekinumab 
treatment was relatively safe with few serious adverse events and all 




































































Figure 4. [A] Ustekinumab interval changes from a starting maintenance interval of q8w during follow-up. [B] Ustekinumab interval changes from a starting 
maintenance interval of q12w during follow-up.
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In our cohort after 52  weeks, 39, 37 and 18% of the patients 
were in clinical, corticosteroid-free clinical remission, and combined 
corticosteroid-free clinical and biochemical remission, respectively. In 
comparison, in the IM-UNITI registration trial, 53% achieved clinical 
and 47% achieved corticosteroid-free clinical remission at week 44.1 
However, only patients with a clinical response [43%, n = 396/912] 
at week 8 were included in the latter analysis1 as a consequence of 
the trial design, in contrast to our real-life cohort that analysed all pa-
tients initiating ustekinumab with clinical disease activity at baseline. 
Interestingly, in our cohort, 31% were in clinical remission according 
to HBI scores at baseline. These patients would not have been able to 
participate in the UNITI studies. Nonetheless, this subgroup of pa-
tients demonstrated baseline disease activity as indicated by biochem-
ical or endoscopic inflammation prior to starting ustekinumab.
Other retrospective observational cohort studies showed com-
parable clinical effectiveness results [n = 162, 27.9% corticosteroid-
free clinical remission at week 52,10 n = 45 35% clinical remission at 
week 129]. A Canadian cohort [n = 62] showed higher effectiveness 
[66.1 and 50.0% clinical and corticosteroid-free clinical remission 
at week 264]. This discrepancy could in part be explained because 
the included patients did not have a history of anti-integrin exposure 
and were predominantly on a q4w interval [77.4%]. We observed 
11 patients on a q4w interval at week 52. The corticosteroid-free 
clinical remission rate was 72.7%, although this result should be 
interpreted with caution because this is a highly selected group of 
patients, escalating to a q4w interval while able to continue therapy 
until week 52. A retrospective real-life Belgian cohort with higher 
prior vedolizumab exposure [69.7%] and higher biochemical disease 
activity at baseline [CRP 16.2 mg/L] showed lower effectiveness rates 
after 52 weeks [25.7% clinical remission and 24.3% corticosteroid-
free clinical remission].11 Another clinically relevant observation was 
that although most patients achieved corticosteroid-free clinical re-
mission already at week 12 [24%, n = 37], some only reached re-
mission at week 24 [15%, n = 23]. This indicates that the onset of 
clinical effects of ustekinumab may require more time beyond the 
formal induction phase for a subgroup of patients.
The present study underlines that ustekinumab is a relatively safe 
treatment. The rates of serious adverse events [4.1 per 100 patient-
years] and severe infections [3.1 per 100 patient-years] were similar 
to those observed in the IM-UNITI trial and other real-world co-
horts.1,7,15 It is important to note that all patients with severe in-
fections were on concomitant immunosuppressant therapies, while 
combination therapy did not provide clinical benefit based on 
corticosteroid-free clinical remission rates in our study. These results 
indicate that ustekinumab monotherapy rather than combination 
therapy should be considered when initiating therapy in CD patients, 
although further studies are warranted to confirm these findings.
We assessed multiple factors that may contribute to the effective-
ness of ustekinumab in CD. Although the difference in therapeutic effi-
cacy between a q8w and q12w interval in the IM-UNITI trial1 was not 
significant, a large proportion of patients in other real-world cohorts6,8 
and in our cohort did receive a q8w interval [85% at week 52]. The 
pharmacokinetic study of the IM-UNITI trial did show a three-fold 
higher median trough concentration in the q8w group compared to 
the q12w group [2.0–2.2  µg/ml vs 0.6–0.8  µg/ml], but this differ-
ence did not translate to a higher proportion of clinical remission.16 
Because the IM-UNITI trial involved a relatively low proportion of 
anti-TNF-exposed patients and no prior anti-integrin exposure, our 
cohort represents a more therapy refractory population, and a thera-
peutic window of ustekinumab trough levels in this setting needs to 
be determined. A Belgian prospective study of 86 anti-TNF- and anti-
integrin-exposed patients suggested that a maintenance trough level 
cut-off of at least 1.9 µg/mL was needed for endoscopic response.17 
However, this was only achieved in half of the patients while all pa-
tients were on a q8w interval. Battat et al. [n = 56, 77% on a q4w 
interval] previously suggested an even higher maintenance target of 
4.5  µg/mL.4 We recognize that further real-world pharmacokinetic 
studies are needed to explain these findings and to assess the value 
of therapeutic drug monitoring in ustekinumab treatment. The out-
come of this future research could have considerable consequences, 
because the cost would increase significantly with a dose escalation of 
one-third [or higher] during the maintenance interval. This informa-
tion, in addition to the comparative effectiveness to other second-line 
biologicals, is important to determine the position of ustekinumab in 
the treatment algorithm for CD.
We also assessed prior exposure to anti-integrin therapy and 
found no significant impact on the corticosteroid-free clinical re-
mission rate at week 52. However, the relatively small sample size 
of the anti-TNF exposed cohort and both the anti-TNF- and anti-
integrin-exposed subcohorts do not allow for firm conclusions. It is 
well known that the clinical response to a second or third anti-TNF 
agent is lower compared to the first anti-TNF agent and that the 
response rate in part depends on the reason for failing the first anti-
TNF.18,19 Furthermore, post-hoc analysis of randomized controlled 
trials have shown lower clinical response rates in patients who are 
anti-TNF experienced when compared to anti-TNF naive for both 
anti-integrin and anti-IL12/23 therapies.1,20 Failure with multiple 
biologicals and especially with multiple classes of biologicals might 
be a surrogate for a more refractory population. Our results show 
that it is still potentially beneficial to start ustekinumab as a third-
line biological and to achieve clinical remission despite prior failure 
of multiple biologicals, including anti-integrins.
Clinical response and remission of peri-anal fistulas were ob-
served in 14.3 and 35.7% of patients, respectively, after 24 weeks 
of treatment. Evidence for fistula closure with ustekinumab is scarce. 
Sands et  al. showed a non-significant improvement of peri-anal 
fistulas after 8  weeks of treatment with ustekinumab compared 
to placebo in the CERTIFI, UNITI-1 and UNITI-2 studies (fistula 
resolution: ustekinumab 24.7% [n  =  37/1306] vs placebo 14.1% 
[n = 10/588], p = 0.07).21 Other real-world cohorts showed fistula 
response rates of up to 66% after 6 months of treatment in six, 12 
and 18 patients.6,7,22 The clinical outcomes for peri-anal fistulas in 
our cohort are promising but require further confirmation in con-
trolled studies.
A beneficial effect of ustekinumab treatment on EIMs was seen in 
35 of the total of 56 [62.5%] patients with reported EIMs at baseline. 
However, 48 patients developed new EIMs during follow-up. Eight 
of 37 arthralgias and one aphthous stomatitis developed in patients 
who were in clinical remission. This finding would favour ongoing 
disease activity in the majority of patients as an explanation for the 
development of arthralgia. This is supported by the assessment of the 
treating physician who reported arthralgia as either an anticipated 
Table 4. Discontinuation visit
Discontinuation visit N = 75
Treatment duration, weeks Median [IQR] 24.6 [15.9–37.8]
Reason for discontinuation   
 Lack of response N [%] 53 [70.7]
 Loss of response N [%] 6 [8.0]
 Adverse events N [%] 8 [10.7]
 Pregnancy N [%] 1 [1.3]
 Request of patient N [%] 6 [8.0]
 Other N [%] 1 [1.3]
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EIM or adverse event. However, disease activity assessment based on 
endoscopy was not available for all patients. In addition, arthralgia 
as an adverse event, or due to tapering of corticosteroids, could not 
be excluded in all patients. To the best of our knowledge this is the 
first cohort of CD patients reporting the effect of ustekinumab treat-
ment on EIMs in a real-world setting. Further studies are warranted 





































































































1 anti-TNF and VDZ
2 anti-TNF and VDZ
Figure 5. [A]: Kaplan–Meier survival curve demonstrating ustekinumab drug persistence. [B] Kaplan–Meier survival curve demonstrating ustekinumab drug 
persistence with a q12w compared to q8w maintenance interval. [C] Kaplan–Meier survival curve demonstrating ustekinumab drug persistence with one or two 
and with or without vedolizumab in their medical history.
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Our study has several strengths. The prospective follow-up 
with a substantial cohort size and a nationwide coverage enabled 
us to create a representative cohort that reflects daily care. The 
characteristics of our cohort [anti-TNF and anti-integrin experi-
enced] allowed us to document clinically relevant effectiveness and 
safety outcomes with ustekinumab beyond trial protocols. Finally, 
ustekinumab route and dosing in our cohort were standardized ac-
cording to the label in contrast to prior published cohorts with het-
erogeneous dosing protocols. Our study also has some limitations. 
Despite the nationwide design of our cohort, most enrolled patients 
are treated in tertiary referral centres. Referral centre bias may limit 
the external validity of our observations when incorporating these 
findings into clinical practice. Another limitation lies in the lack of 
systematic information regarding endoscopic remission. Since this 
is an observational cohort not all centres performed endoscopy sys-
tematically to assess response. Most centres perform endoscopy or 
imaging only if information from non-invasive biomarkers is incon-
clusive, furthermore the time points of endoscopy differ. Selection 
bias would therefore probably be present when reporting these data. 
The comparison of effectiveness between specific subgroups should 
be interpreted with care because there was no correction for bias and 
potential confounders. However, because the baseline characteristics 
were largely comparable, these exploratory analyses may be used for 
future randomized research to determine the true effect of different 
treatment strategies. Lastly, this is an ongoing registry which still 
actively recruits patients. Therefore, not all patients were followed 
for the same time period. We intended to limit this bias by censoring 
the patients with inadequate follow-up time both with and without 
clinical response.
In conclusion, ustekinumab showed clinical effectiveness 
and was relatively safe in a real-life cohort of biological-exposed 
CD patients. A  substantial proportion of the patients achieved 
corticosteroid-free clinical remission, inflammatory biomarker re-
duction and clinical peri-anal fistula closure. A  q8w interval was 
associated with a reduced discontinuation rate, while concomitant 
use of immunosuppressants did not have a significant impact on the 
therapeutic effectiveness of ustekinumab in our cohort. These result 
underline the value of ustekinumab in managing refractory CD pa-
tients. However, further research is warranted to determine the pre-
cise place of ustekinumab in the treatment algorithm of CD.
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